Showing results (41-50 of 73) with videos related to
Sort By:
Pageof 8
Addiction Biology|June 16, 2009
Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapyCandice Jamois, Patrick Smith, Royce Morrison, et al.International Journal of Clinical Pharmacology and Therapeutics|June 28, 2012
Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteersChristophe Schmitt, Anne Charoin-Pannier, Christine McIntyre, et al.Thrombosis Research|March 26, 2013
Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studiesDorothee Kling, Corinne Stucki, Sven Kronenberg, et al.Langmuir : the ACS Journal of Surfaces and Colloids|October 30, 2013
Heteroprotein complex coacervation: bovine β-lactoglobulin and lactoferrinYunfeng Yan, Ebru Kizilay, Daniel Seeman, et al.Arthritis Research & Therapy|June 6, 2022
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging studyChristophe Schmitt, Laura Brockwell, Mylène Giraudon, et al.Clinical Pharmacokinetics|December 8, 2017
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia AKoichiro Yoneyama, Christophe Schmitt, Naoki Kotani, et al.Expert Review of Clinical Pharmacology|August 2, 2023
Clinical pharmacology of emicizumab for the treatment of hemophilia AKoichiro Yoneyama, Christophe Schmitt, Agnès Portron, et al.The Journal of Physical Chemistry. B|July 12, 2024
Modulating Weak Protein-Protein Cross-Interactions by the Addition of Free Amino Acids at Millimolar ConcentrationsPamina M Winkler, Cécilia Siri, Johann Buczkowski, et al.Soft Matter|August 8, 2014
Structure of bovine β-lactoglobulin-lactoferrin coacervatesEbru Kizilay, Daniel Seeman, Yunfeng Yan, et al.Journal of Cardiovascular Pharmacology|February 26, 2015
First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectinChristophe Schmitt, Markus Abt, Cornelia Ciorciaro, et al.Pageof 8